← All news

FROM THE NEWS FEED

Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026

2026-09-10 β€’ Psychedelic Invest

Article summary

NEW YORK, September 10, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to…

Continue to the original publication for the complete article.